Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Simultaneous quantification of antibody-RNA conjugates and the transcriptome from fixed cells by RAID

ABSTRACT: Simultaneous quantification of antibody-RNA conjugates and the transcriptome from fixed cells by RAID

PROVIDER: PRJNA476554 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7357194_1.fastq.gz	Fastqsanger.gz
	SRR7357194_2.fastq.gz	Fastqsanger.gz
	SRR7357195_1.fastq.gz	Fastqsanger.gz
	SRR7357195_2.fastq.gz	Fastqsanger.gz
	SRR7357196_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Simultaneous quantification of antibody-RNA conjugates and the transcriptome from fixed cells by RAID

Project description:Undifferentiated and differentiated Keratinocytes (AG1478 treated) were stained with antibody-RNA conjugates to measure protein-based diffrentiation changes in conjunction with single-cell transcriptomics. The cells were crosslinked and stained according to the RAID procedure to allow intracellular immunostaining. Antibodies used in this experiment are (TGM1, NOTCH1, KLK6, JAG1, phospho-RPS6, phospho-FAK).

2019-02-13 | GSE115937 | GEO

Simultaneous quantification of antibody-RNA conjugates and the transcriptome by single cell RNA-sequencing

Project description:Simultaneous quantification of antibody-RNA conjugates and the transcriptome by single cell RNA-sequencing

| PRJNA476555 | ENA

Simultaneous quantification of antibody-RNA conjugates and the transcriptome by single cell RNA-sequencing

Project description:Undifferentiated and differentiated Keratinocytes (AG1478 treated) were stained with antibody-RNA conjugates (targeting EGFR and ITGA6) to measure protein-based differentiation changes in conjunction with single-cell transcriptomics.

2019-02-13 | GSE115936 | GEO

Immune-stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity

Project description:Immune-stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity

| PRJNA663153 | ENA

Low-input RNase footprinting for simultaneous quantification of cytosolic and mitochondrial translation

Project description:Low-input RNase footprinting for simultaneous quantification of cytosolic and mitochondrial translation

| PRJNA638017 | ENA

Immune-stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity I

Project description:Immune-stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity I

| PRJNA662959 | ENA

Immune-stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity II

Project description:Immune-stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity II

| PRJNA663155 | ENA

Development of potent antibody drug conjugates against ICAM1+ cancer cells in preclinical models of cholangiocarcinoma

Project description:Development of potent antibody drug conjugates against ICAM1+ cancer cells in preclinical models of cholangiocarcinoma

| PRJNA978044 | ENA

RAID allows multiplexed quantification of intracellular (phospho-)proteins and transcriptomes from fixed single cells

Project description:RAID allows multiplexed quantification of intracellular (phospho-)proteins and transcriptomes from fixed single cells

| PRJNA476686 | ENA

Immune-stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity II

Project description:Innate pattern recognition receptors, including toll-like receptors (TLRs), can alter the tumor microenvironment and prime adaptive anti-tumor immunity. However, TLR agonists have not been well-tolerated due to toxicities associated with widespread immune activation following systemic administration. To design a therapeutic that is suitable for systemic delivery and capable of eliciting a tumor-targeted response, we developed a novel class of immune-stimulating antibody conjugates (ISACs) comprising a TLR7/8 agonist conjugated to tumor-targeting antibodies. Systemically administered anti-HER2 ISACs were well-tolerated in vivo and elicited robust activation of intratumoral myeloid cells, resulting in tumor clearance and subsequent immunological memory. In vitro potency and in vivo efficacy required tandem activity driven by intact Fc functionality and TLR agonism to enable phagocytosis and T cell-mediated anti-tumor immunity. ISAC-mediated immunological memory was not limited to HER2, as ISAC-treated mice were protected from rechallenge with a HER2-negative tumor. These results provide strong rationale for the clinical development of ISACs and show that synergy between FcgR and TLR7/8 signaling contributes to the mechanism of ISAC-mediated anti-tumor immunity.

2020-12-03 | GSE157869 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data